Beyond the Endpoint

Duke Clinical Research Institute

Wissenschaft

Neueste Episode

Verfügbare Folgen

5 von 39

From Provider to Patient: A Dual Perspective on Colorectal Cancer
Hosts Emily O’Brien and Manesh Patel sit down with Dr. Ajay Kohli and Dr. Julius Wilder for a dual-perspective conversation on colorectal cancer, where they discuss personal experiences, the importance of early detection, screening disparities, and how equitable access to care saves lives. 🔗Access resources related to this episode: https://dcri.org/blog/s2-ep-7-provider-patient-dual-perspective-colorectal-cancer
--------
38:40
--------
38:40
Beyond the Headlines: Recap of the 2025 AHA Scientific Sessions
Recorded at the 2025 American Heart Association Scientific Sessions, hosts Manesh Patel and Emily O'Brien discuss late-breaking cardiovascular research, including gene-editing therapy for cholesterol, AFib management strategies, and, for coffee lovers, the DECAF trial's findings on caffeine and heart rhythm. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-6-beyond-headlines #AHA25 #beyondtheendpoint #cardiology #podcast #hearthealth #clinicalresearch
--------
20:42
--------
20:42
Connecting the Dots: The Broader Applications of GLP-1s and Where We’re Headed Next
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-5-connecting-dots-broader-applications-glp-1s-and-where-were-headed-next
--------
36:41
--------
36:41
Obesity, GLP-1s, and the Evidence: What the Data Tells Us
In this second episode of our obesity series, preventive cardiologist Neha Pagidipati sheds light on the discovery, impact, and uses of GLP-1s, like Ozempic and Mounjaro. Learn about the impact these medications are having on diabetes, heart disease, and weight management. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-4-obesity-glp-1s-and-evidence-what-data-tells-us
--------
31:04
--------
31:04
It's Not Just the Scale: Supporting Sustainable Change in Obesity Treatment
In the first of a three-part series on obesity and GLP-1 medications, our guest Jennifer Norris shares the evolving landscape of obesity treatment. The conversation addresses common misconceptions and examines how GLP-1 medications, such as Ozempic, have transformed care alongside surgery and lifestyle interventions.
--------
32:14
--------
32:14

Weitere Wissenschaft Podcasts

Über Beyond the Endpoint

The Duke Clinical Research Institute is drawing on gold-standard research and real-world evidence to bring you Beyond the Endpoint, a podcast that is demystifying clinical research and healthcare through conversations with renowned clinicians and scientists.

Podcast-Website

Wissenschaft